News ESMO 2019 - Amgen’s KRAS drug finds colorectal cancer a chal... Amgen’s KRAS inhibitor AMG 510 has shown little effect in colorectal cancer patients, according to new data reported at the
Views & Analysis Merck KGaA's bold new approach to cancer immunotherapy Germany’s Merck KGaA is hoping to stand out from the crowd with a bold new approach to cancer immunotherapy.
Views & Analysis ESMO round-up: Big win for AstraZeneca in ovarian cancer, an... Several drugmakers announced significant trial findings at this week’s European Society for Medical Oncology (ESMO) conference in Munich.
News Tagrisso on target to be EGFR+ lung cancer standard New phase 3 data presented at ESMO earlier today suggests Tagrisso could be a major step forward in treating patients with EGFR positive non-small cell lung cancer.
News Rubraca outshines rivals in ovarian cancer maintenance thera... Clovis' Rubraca, the drug showing significant benefits for all ovarian cancer patients in a maintenance setting – and better results than its rivals.
News PBM reform dropped in Congress' funding package Proposed reforms to the regulations for PBMs were dropped from the US Congress' end-of-year bill to provide funding to the federal government.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
